Cantor Fitzgerald Has Positive View of TSHA FY2025 Earnings

Taysha Gene Therapies, Inc. (NASDAQ:TSHA - Free Report) - Investment analysts at Cantor Fitzgerald boosted their FY2025 earnings per share estimates for Taysha Gene Therapies in a research note issued on Thursday, June 12th. Cantor Fitzgerald analyst K. Kluska now anticipates that the company will earn ($0.33) per share for the year, up from their previous estimate of ($0.36). Cantor Fitzgerald has a "Overweight" rating and a $7.00 price target on the stock. The consensus estimate for Taysha Gene Therapies' current full-year earnings is ($0.35) per share. Cantor Fitzgerald also issued estimates for Taysha Gene Therapies' FY2026 earnings at ($0.38) EPS.

Several other research analysts have also commented on the stock. JMP Securities raised their price target on shares of Taysha Gene Therapies from $5.00 to $6.00 and gave the company a "market outperform" rating in a report on Thursday, May 29th. Needham & Company LLC restated a "buy" rating and set a $8.00 target price on shares of Taysha Gene Therapies in a report on Tuesday, June 10th. Canaccord Genuity Group increased their price target on Taysha Gene Therapies from $9.00 to $11.00 and gave the company a "buy" rating in a report on Tuesday, June 3rd. Chardan Capital raised their price objective on Taysha Gene Therapies from $7.00 to $9.00 and gave the company a "buy" rating in a research report on Thursday, May 29th. Finally, Citigroup reaffirmed an "outperform" rating on shares of Taysha Gene Therapies in a research report on Thursday, May 29th. Eight investment analysts have rated the stock with a buy rating, Based on data from MarketBeat, the stock presently has a consensus rating of "Buy" and an average target price of $7.57.

Taysha Gene Therapies Trading Up 0.8%

Shares of Taysha Gene Therapies stock traded up $0.02 during trading hours on Monday, reaching $2.57. The stock had a trading volume of 3,282,567 shares, compared to its average volume of 3,048,919. The firm has a market capitalization of $551.68 million, a price-to-earnings ratio of -7.56 and a beta of 1.04. Taysha Gene Therapies has a 1 year low of $1.05 and a 1 year high of $3.31. The company has a current ratio of 5.35, a quick ratio of 5.35 and a debt-to-equity ratio of 0.77. The firm has a 50 day simple moving average of $2.26 and a two-hundred day simple moving average of $1.92.

Taysha Gene Therapies (NASDAQ:TSHA - Get Free Report) last posted its quarterly earnings results on Thursday, May 15th. The company reported ($0.08) EPS for the quarter, meeting the consensus estimate of ($0.08). Taysha Gene Therapies had a negative return on equity of 104.93% and a negative net margin of 1,201.08%. The company had revenue of $2.30 million during the quarter, compared to analysts' expectations of $1.48 million. During the same quarter in the previous year, the business earned ($0.10) EPS.

Institutional Investors Weigh In On Taysha Gene Therapies

A number of hedge funds have recently bought and sold shares of the business. Octagon Capital Advisors LP boosted its stake in Taysha Gene Therapies by 128.6% during the 4th quarter. Octagon Capital Advisors LP now owns 10,450,000 shares of the company's stock valued at $18,078,000 after acquiring an additional 5,877,778 shares during the last quarter. Adage Capital Partners GP L.L.C. acquired a new stake in shares of Taysha Gene Therapies in the 4th quarter valued at about $8,650,000. Bank of America Corp DE lifted its position in shares of Taysha Gene Therapies by 1,178.9% during the fourth quarter. Bank of America Corp DE now owns 1,710,303 shares of the company's stock worth $2,959,000 after purchasing an additional 1,576,568 shares during the last quarter. Norges Bank acquired a new position in Taysha Gene Therapies in the fourth quarter worth about $2,528,000. Finally, Avoro Capital Advisors LLC increased its holdings in Taysha Gene Therapies by 7.2% in the fourth quarter. Avoro Capital Advisors LLC now owns 19,999,999 shares of the company's stock valued at $34,600,000 after buying an additional 1,349,999 shares during the last quarter. Institutional investors and hedge funds own 77.70% of the company's stock.

Insider Activity

In other Taysha Gene Therapies news, major shareholder Paul B. Manning purchased 750,000 shares of the business's stock in a transaction that occurred on Friday, May 30th. The shares were acquired at an average price of $2.75 per share, for a total transaction of $2,062,500.00. Following the completion of the purchase, the insider now owns 2,841,704 shares in the company, valued at $7,814,686. The trade was a 35.86% increase in their position. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Insiders own 3.78% of the company's stock.

Taysha Gene Therapies Company Profile

Taysha Gene Therapies, Inc, a gene therapy company, focuses on developing and commercializing adeno-associated virus-based gene therapies for the treatment of monogenic diseases of the central nervous system. It primarily develops TSHA-120 for the treatment of giant axonal neuropathy; TSHA-102 for the treatment of Rett syndrome; TSHA-121 for the treatment of CLN7 disease; TSHA-118 for the treatment of CLN1 disease; TSHA-105 for the treatment of for SLC13A5 deficiency; TSHA-113 for the treatment of tauopathies; TSHA-106 for the treatment of angelman syndrome; TSHA-114 for the treatment of fragile X syndrome; and TSHA-101 for the treatment of GM2 gangliosidosis.